uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Aiding sleep in type 2 diabetes: therapeutic considerations
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.ORCID iD: 0000-0003-3992-5812
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.ORCID iD: 0000-0002-9052-8372
Show others and affiliations
2018 (English)In: The Lancet Diabetes and Endocrinology, ISSN 2213-8587, E-ISSN 2213-8595, Vol. 6, no 1, p. 60-68Article, review/survey (Refereed) Published
Abstract [en]

Insomnia and obstructive sleep apnoea (OSA) are more prevalent in patients with type 2 diabetes than in the general population. Both insomnia and OSA have been linked to cardiometabolic alterations (eg, hypertension, increased activity of the sympathetic nervous system, and systemic insulin resistance) that can exacerbate the pathophysiology of type 2 diabetes. Improvement of sleep in patients with diabetes could therefore aid the treatment of diabetes. To help health practitioners choose the best clinical tool to improve their patients' sleep without detrimentally affecting glucose regulation, this Review critically analyses the effects of common treatments for insomnia and OSA on both sleep and glucose metabolism in patients with type 2 diabetes. These treatments include pharmaceutical sleep aids (eg, benzodiazepine receptor agonists, melatonin) and cognitive behavioural therapy for insomnia, continuous positive airway pressure for OSA, and lifestyle interventions.

Place, publisher, year, edition, pages
2018. Vol. 6, no 1, p. 60-68
National Category
Endocrinology and Diabetes Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-342756DOI: 10.1016/S2213-8587(17)30233-4ISI: 000423799900020PubMedID: 28844889OAI: oai:DiVA.org:uu-342756DiVA, id: diva2:1185056
Funder
Novo NordiskSwedish Research CouncilAFA InsuranceSwedish Society of MedicineThe Swedish Brain Foundation√Öke Wiberg FoundationLars Hierta Memorial FoundationAvailable from: 2018-02-23 Created: 2018-02-23 Last updated: 2018-05-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Tan, Xiaovan Egmond, LieveChapman, Colin DCedernaes, JonathanBenedict, Christian

Search in DiVA

By author/editor
Tan, Xiaovan Egmond, LieveChapman, Colin DCedernaes, JonathanBenedict, Christian
By organisation
Functional Pharmacology
In the same journal
The Lancet Diabetes and Endocrinology
Endocrinology and DiabetesPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf